학술논문
Survival outcomes of breast cancer patients with recurrence after surgery according to period and subtype.
Document Type
Academic Journal
Author
Lee YJ; Department of Surgery, Division of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Yoo TK; Department of Surgery, Division of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Kim J; Department of Surgery, Division of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Chung IY; Department of Surgery, Division of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Ko BS; Department of Surgery, Division of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Kim HJ; Department of Surgery, Division of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Lee JW; Department of Surgery, Division of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Son BH; Department of Surgery, Division of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Ahn SH; Department of Surgery, Division of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Lee SB; Department of Surgery, Division of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Source
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
Subject
Language
English
Abstract
Purpose: To analyze and compare the survival rates of recurrent breast cancer patients in Korea between two periods (period I: 2000-2007; period II: 2008-2013) and to identify the factors associated with outcomes and changes over time in the duration of survival after recurrence.
Methods: We retrospectively analyzed 2,407 patients who had recurrent breast cancer with treated between January 2000 and December 2013 and divided them into two periods according to the year of recurrence. We reviewed the age at diagnosis, clinical manifestations, pathology report, surgical methods, types of adjuvant treatment, type of recurrence, and follow-up period.
Results: The median follow-up was 30.6 months (range, 0-223.4) from the time of relapse, and the median survival time was 42.3 months. Survival after recurrence (SAR) significantly improved from 38.0 months in period I to 49.7 months in period II (p < 0.001). In the analysis performed according to the hormone receptor and HER2 status subtypes, all subtypes except the triple-negative subtype showed higher SAR in period II than period I. Age at diagnosis, tumor stage, and treatment after recurrence were significantly correlated with survival outcomes.
Conclusion: The survival outcomes of Korean patients with breast cancer after the first recurrence have improved in Korea. Such improvements may be attributed to advances in treatment.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Lee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Methods: We retrospectively analyzed 2,407 patients who had recurrent breast cancer with treated between January 2000 and December 2013 and divided them into two periods according to the year of recurrence. We reviewed the age at diagnosis, clinical manifestations, pathology report, surgical methods, types of adjuvant treatment, type of recurrence, and follow-up period.
Results: The median follow-up was 30.6 months (range, 0-223.4) from the time of relapse, and the median survival time was 42.3 months. Survival after recurrence (SAR) significantly improved from 38.0 months in period I to 49.7 months in period II (p < 0.001). In the analysis performed according to the hormone receptor and HER2 status subtypes, all subtypes except the triple-negative subtype showed higher SAR in period II than period I. Age at diagnosis, tumor stage, and treatment after recurrence were significantly correlated with survival outcomes.
Conclusion: The survival outcomes of Korean patients with breast cancer after the first recurrence have improved in Korea. Such improvements may be attributed to advances in treatment.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Lee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)